Economy
Dutch Pharmaceutical Executive Foresees 'Golden Decade' for Cheaper Medicines
Remco Steenbergen, financial director at Sandoz, anticipates price reductions of up to 70% for widely used cancer medications as numerous patents expire in the coming years. This shift is expected to drive significant cost savings and improve accessibility to essential treatments.
Ozetta summarises; the reporting is the newsroom's